Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Improved survival after post-transplant relapse of adult t-cell leukemia-lymphoma and trends of salvage therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

AIAyumu ItoTETetsuya EtoMFMachiko Fujioka

Discussion

Loading...

Member takes

Overview

Observational analysis found improved survival trends following post-transplant relapse in adult T-cell leukemia-lymphoma, indicating novel therapies show promise.

Key Points

  • Survival trends after post-transplant relapse improved in the late period for adult T-cell leukemia-lymphoma.
  • 1-year overall survival rates for the Refractory group increased to 17.1% in the late period.
  • Cox proportional hazards regression models analyzed outcomes for 1146 patients experiencing R/R ATL.
  • Introduction of novel agents like mogamulizumab and lenalidomide may enhance post-transplant therapeutic options.

Cite This Study

Ito et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc8fhttps://doi.org/10.1182/blood-2025-562
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Three decades of allogeneic transplantation showing improved survival, persistent relapse and post‑relapse outcomes of donor lymphocyte infusion versus second transplant2025
  2. 2Treatment Strategies of Acute Myeloid Leukemia Relapses after Allogeneic Stem Cell Transplantation: Evidence from the GITMO Nationwide Italian Registry2025 · 1 citations
  3. 3Differential trends in survival after allogeneic transplantation for MDS and MDS/MPN in a real-world experience2025
  4. 4Revisiting the role of second allogeneic HCT for post-transplant relapse in acute lymphoblastic leukemia: Comparative outcomes in the era of targeted therapies2025
  5. 5Predictors of survival with and without allogeneic stem cell transplantation after first salvage therapy with blinatumomab and/or inotuzumab ozogamicin for Relapsed/Refractory B-cell acute lymphoblastic leukemia2025 · 1 citations